Tribune Therapeutics is a pre-clinical stage biopharmaceutical company developing novel biological drugs to treat patients with fibrotic diseases, including diseases affecting the kidney, lung and liver. Based on research from Håvard Attramadal‘s lab at Oslo University Hospital, Tribune’s medicines target the CCN protein family. The CCN protein family is a group of signalling proteins central […]
xFOREST Therapeutics is a Japanese startup developing a platform for targeting disease-related RNA structures with small molecules. The company’s platform enables the search for highly specific RNA-binders, empowering the rapid and efficient discovery of RNA-targeting drugs. Tens of thousands of RNAs and tens of thousands of compounds from libraries can be analyzed in parallel with […]
Angios is developing new treatments for challenging vascular diseases using the vascular organoid model developed by the company’s founders. The vascular organoids allow the company to model human microvascular complications in the dish and thereby find new pathways associated with disease progression. Diseases affecting blood vessel functionality remain an unresolved global health problem, especially in […]
MoonLake Immunotherapeutics is a Swiss biopharmaceutical company leveraging single-domain antibody (Nanobody®) technology to develop medicines for immunologic diseases, including inflammatory skin and joint diseases. Nanobodies® are proprietary therapeutic proteins based on single-domain antibody fragments, with the benefits of conventional antibodies but at 1/10th the size. MoonLake has licensed Merck KGaA’s phase 3-ready drug sonelokimab (M1095) […]
ResBiotic is developing microbiome-based products to help reduce inflammation in chronic lung diseases. The company is building on research into how the microbiota influence lung diseases, carried out by company founder and Chief Scientific Officer C. Vivek Lal at University of Alabama at Birmingham. Chronic respiratory illness is associated with lung dysbiosis (abnormal lung microbiome) […]
Alchemab identifies naturally occurring protective antibodies that counter complex diseases, such as cancer and neurodegenerative diseases, by mining the antibody repertoires of individuals who are resistant to or recovered from disease. Alchemab’s approach was developed with support from scientific founders at Oxford University, Johns Hopkins University and Mount Sinai Hospital. The company’s approach starts by […]
Israel-based Wild Biotech is mining wild animal microbiomes for the discovery of novel human therapeutics, based on the “largest database ever assembled of the microbiome of wild animals”. Based on work published in Science, the company’s founders have sampled the faeces of 184 wild animals, including fish, birds, and mammals, from four different continents to […]
MUVON Therapeutics is spin-off from the University of Zurich developing an autologous cell therapy for the treatment of diseases related to skeletal muscle damage or degradation. The technology behind MUVON was developed over the past decade at the University of Zurich and in recent years has been funded by the EU under the Horizon 2020 […]
Founded in 2020, Chimerna Therapeutics has developed a platform for generating circular RNA, which overcomes the major limitations of RNA therapeutics, namely stability and abundance. The company says this proprietary technology makes robust endogenous expression of RNAs and RNA aptamers possible. By making RNA as a circle, rather than the normal linear form that predominates […]
Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies, which it says overcome several of the major challenges with current degradation platforms, including oral bioavailability and CNS exposure. Founded in 2020 and based in Cambridge, UK, the company builds on work carried out in the Gunning Group at […]